| abstract |
A method is described for treating diseases in which TNFα activity is detrimental by subcutaneous administration of a human antibody, preferably a recombinant human antibody, which specifically binds to human tumor necrosis factor α (hTNFα). The antibody is administered with methotrexate or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K d = 10 -8 M or less) and exhibit slow dissociation rates (e.g., K off = 10 -3 sec -1 or less) for hTNFa dissociation, in vitro and Neutralizes hTNFα activity in vivo. Antibodies of the invention may be full-length antibodies or antigen-binding portions thereof. Kits containing the pharmaceutical composition and instructions for administration, and prefilled syringes containing the pharmaceutical composition are also included in the present invention. |